In her latest On target column published by the ESMO Daily Reporter, VHIO’s Elena Garralda discusses the expanding toolbox for immuno-oncology in advanced solid tumors. Illustrative of promising data from several early clinical trials in cancer immunotherapy, recently presented at the ESMO Congress 2024 (13-17 September, Barcelona), she briefly highlights a handful of studies that showed encouraging antitumor actions and activity and comments on the emerging field of oncolytic virotherapy in patients with advanced/metastatic disease.
Addressing the challenges ahead in bringing novel approaches and treatment strategies to the clinic, Elena suggests that further evaluation in expanded cohorts will be required and, where possible, additional study designs allowing crossover could help to reduce the potential side-effects of immunotherapy against cancer.
To further boost precision immunotherapy, she also discusses the importance of translating basic cancer science into therapeutic tools and advances in patient treatment and care, including efforts aimed at better predicting response to immune-based therapy in oncology.
We invite you to read her latest column here. To browse all previous editions of On target, please click here.
Elena Garralda is Director of VHIO’s Research Unit for Molecular Therapy of Cancer (UITM) – CaixaResearch, Head of our Early Clinical Drug Development Group, and co-Director of VHIO’s Clinical Research Program.
